Your browser doesn't support javascript.
loading
The Importance of Tracking "Missing" Metabolites: How and Why?
Wang, Shuai; Ballard, T Eric; Christopher, Lisa J; Foti, Robert S; Gu, Chungang; Khojasteh, S Cyrus; Liu, Joyce; Ma, Shuguang; Ma, Bin; Obach, R Scott; Schadt, Simone; Zhang, Zhoupeng; Zhang, Donglu.
Affiliation
  • Wang S; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Ballard TE; Takeda Development Center Americas, Inc., 35 Landsdowne St, Cambridge, Massachusetts 02139, United States.
  • Christopher LJ; Department of Clinical Pharmacology, Pharmacometrics, Disposition & Bioanalysis, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States.
  • Foti RS; Preclinical Development, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.
  • Gu C; Drug Metabolism and Pharmacokinetics, Biogen Inc., 225 Binney Street, Cambridge, Massachusetts 02142, United States.
  • Khojasteh SC; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Liu J; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Ma S; Drug Metabolism and Pharmacokinetics, Pliant Therapeutics, 260 Littlefield Avenue, South San Francisco, California 94080, United States.
  • Ma B; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Obach RS; Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., Eastern Point Road, Groton, Connecticut 06340, United States.
  • Schadt S; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacher Strasse 124, 4070 Basel, Switzerland.
  • Zhang Z; DMPK Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
  • Zhang D; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
J Med Chem ; 66(23): 15586-15612, 2023 12 14.
Article in En | MEDLINE | ID: mdl-37769129
Technologies currently employed to find and identify drug metabolites in complex biological matrices generally yield results that offer a comprehensive picture of the drug metabolite profile. However, drug metabolites can be missed or are captured only late in the drug development process. This could be due to a variety of factors, such as metabolism that results in partial loss of the molecule, covalent bonding to macromolecules, the drug being metabolized in specific human tissues, or poor ionization in a mass spectrometer. These scenarios often draw a great deal of attention from chemistry, safety assessment, and pharmacology. This review will summarize scenarios of missing metabolites, why they are missing, and associated uncovering strategies from deeper investigations. Uncovering previously missed metabolites can have ramifications in drug development with toxicological and pharmacological consequences, and knowledge of these can help in the design of new drugs.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Development Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Development Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States